Close Menu

NEW YORK — Natera on Tuesday filed with the US Securities and Exchange Commission for a follow-on public offering of its common stock worth up to $201.3 million.

The San Carlos, California-based company also said on Tuesday that it expects its third quarter revenues to be in the range of $74 million to $76 million, topping Wall Street's consensus estimate of $73.5 million. The company said it processed around 200,000 tests in the third quarter, representing approximately 20 percent growth over the year-ago quarter. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.